Zobrazeno 1 - 10
of 955
pro vyhledávání: ''
Autor:
Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, Norihiko Ikeda
Publikováno v:
Cancer Science. 113:1002-1009
Although adjuvant tegafur/uracil (UFT) is recommended for patients with completely resected stage I non-small cell lung cancer (NSCLC) in Japan, only one-third of cases has received adjuvant chemotherapy according to real-world data. Therefore, robus
Autor:
Yan Yuan, Zhifan Zeng, Rong-Zhen Li, Weiwei Xiao, Hui Chang, Qiaoxuan Wang, Yuanhong Gao, Wei-Hao Xie
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 117-127 (2022)
Cancer Medicine
Cancer Medicine
Background Anal squamous cell carcinoma (ASCC) is a rare malignant tumor with increasing incidence. The goal of our study was to analyze the treatment outcome and prognostic factors of ASCC in South China in the past half‐century. Methods This stud
Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics
Autor:
Young Chandler, Clyde Schechter, Jinani Jayasekera, Claudine Isaacs, Allison W. Kurian, Christopher Cadham, Jeanne Mandelblatt
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 2, Pp 297-307 (2022)
Cancer Medicine, Vol 11, Iss 2, Pp 297-307 (2022)
Background Extending endocrine therapy from 5 to 10 years is recommended for women with invasive estrogen receptor (ER)‐positive breast cancers. We evaluated the benefits and harms of the five additional years of therapy. Methods An established Can
Autor:
Gyungyub Gong, Min Jeong Song, Kyung-Ja Cho, Ji-Seon Jeong, Yong Mee Cho, Uiree Jo, Joon Seon Song
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8899-8908 (2021)
Cancer Medicine
Cancer Medicine
Introduction A pericardial effusion (PE) has a variable etiology and the primary role is diagnosis of metastatic malignancy. We analyzed the PE cytology in a large cohort in accordance with the international system for reporting serous fluid cytopath
Autor:
Jinyi Wang, Guohan Chen, Guangxue Wang, Xuan Hong, Zhiyuan Huang, Tian Zhao, Yejun Cao, Qiying Zhang, Zhengjun Chai, Jie Liu, Qinchuan Li, Yang Han, Zhengliang Sun
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 2, Pp 348-357 (2022)
Cancer Medicine, Vol 11, Iss 2, Pp 348-357 (2022)
Objective The aim of this study was to assess the efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy (IPHC) in treating malignant pleural effusion (MPE) compared to normothermic chemoperfusion of the pleural cavity (NCPC), a
Autor:
Tam N M Ngo, Jan Mazur, Eugene S. Chung, Huy Gia Vuong, Vien T. Truong, Vy T. Pham, Binh Q Truong, Quoc Bui, Cassady Palmer
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8838-8845 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8838-8845 (2021)
Background The survival outcome for primary cardiac malignant tumors (PMCTs) based on race has yet to be fully elucidated in previously published literature. This study aimed to address the general long‐term outcome and survival rate differences in
Autor:
Atsushi Nakamura, Shunsuke Teraoka, Naohisa Matsumoto, Kazuhiko Nakagawa, Akito Hata, Satoshi Ikeda, Nobuyuki Yamamoto, Motohiro Tamiya, Shinya Sakata, Satoru Miura, Kentaro Ito, Hiroshige Yoshioka, Yoshimasa Shiraishi, Shota Omori, Junko Tanizaki, Koji Haratani, Hisako Yoshida, Kohei Otsubo
Publikováno v:
Cancer Science
Considering the increasing number of identified driver oncogene alterations, additional genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (NSCLC). Next‐generation sequencing can detect multiple driver
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Nicholas J Robert, Marley Boyd, Shrujal S. Baxi, Aaron B Cohen, Yanina Natanzon, Olga Tymejczyk, Mark Stewart, Laura Lasiter, Elizabeth Garrett-Mayer, Donna R. Rivera, Jeff Allen, Monika A Izano, Eric Hansen, Mackenzie Small, Jennifer B. Christian, Andrew J. Belli, Joseph Wagner, Janet L. Espirito, Connor Sweetnam
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:444-454
In prior work, Friends of Cancer Research convened multiple data partners to establish standardized definitions for oncology real-world end points derived from electronic health records (EHRs) and claims data. Here, we assessed the performance of rea
Autor:
Lucile Bussot, Simon Chevalier, Caroline Algrin, Anouk Emadali, Laurence David-Boudet, Christine Lefebvre, Cyril Fournier, Laurent Martin, Claire Vettier, O. Casasnovas, Remy Gressin, Caroline Chapusot, Mary Callanan, Edwige Col, Thierry Bonnefoix, Marie-Christine Jacob, Anne McLeer, Antonin Bouroumeau, Tatiana Raskovalova, Hervé Sartelet
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 7, Iss 6, Pp 604-615 (2021)
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research
Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will relapse. Ove